Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial


Posted in: Drug Trial News | Medical Condition News

Tags: Anemia, Angioedema, Anorexia, Anti-Inflammatory, Arthralgia, Back Pain, Basal Cell Carcinoma, Birth Control, birth defects, Blood Donation, Cancer, Carcinoma, Cell, Chronic Lymphocytic Leukemia, Chronic Obstructive Pulmonary Disease, Clostridium difficile, Congestive Heart Failure, Constipation, Contraception, Cough, Diabetes, Dialysis, Diarrhea, Dysgeusia, Dyspnea, Edema, Epistaxis, Estrogen, Fever, Gene, Headache, Heart Failure, Hypersensitivity, Lactose Intolerance, Leukemia, Leukopenia, Liver Disease, Lymph Node, Lymphoma, Multiple Myeloma, Muscle, Myeloma, Nausea, Neutropenia, Nursing, Pain, Peripheral Edema, Pharyngitis, Placebo, Pneumonia, Pregnancy, Protein, Pruritus, Pulmonary Embolism, Respiratory, Revlimid, Semen, Sepsis, Sperm, Stem Cell, Thalidomide, Thrombocytopenia, Thrombosis, tumor, Vasectomy, Venous Thromboembolism, Warfarin